Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), or programmed cell death protein 1 (PD-1) and its ligand (PD-L1) interaction have shifted the treatment paradigms and significantly improve the overall survival (OS) in diverse cancers (1–4). This evidence concerns the gene CD274 and cancer.